Page 1 of 6
This document provides a short summary of this study for a general audience. You can
find more information in the scientific summary of the study. A link to the summary is
provided at the end of this document.
Study names
Short Title: A study to see how well a combination of dolutegravir and lamivudine
works when given right after adults are newly diagnosed with HIV.
Full Scientific Title: A Phase 3b multi-centre, open label, single arm, 52-week pilot
study, evaluating the feasibility, efficacy and safety of a rapid test and treat
intervention in newly diagnosed HIV-1 infected adults using a fixed dose combination
of dolutegravir plus lamivudine as a first line regimen.
ViiV Healthcare Study Number: 212355
Who sponsored this study?
ViiV Healthcare
GSK Clinical Support Help Desk
Website: clinicalsupporthd.gsk.com/contact.html
Email: GSKClinicalSupportHD@gsk.com
General information about the clinical study
When and where was this study done?
The study started in July 2019 and ended in October 2020. All study sites were in
United States.
What was the main objective of this study?
Human immunodeficiency virus type 1 (HIV) damages the bodyâ€™s defence system
(immune system). It weakens the ability to fight infections and increases the risk of
developing diseases. Doctors monitor the amount of HIV in the body (viral load) by
measuring HIV RNA levels in the blood.
Use of the data and information contained in this Document is unrestricted, provided that it may not
be used in applications by others for regulatory approval of a product. While not required, when using
these data, we ask that proper credit or attribution of ViiV Healthcare as the source of the data be
given. ViiV Healthcare/GSK disclaims liability for all uses of the data by users of this Document, to the
fullest extent permitted by applicable law. No trademark, patent, or regulatory/data exclusivity rights
held by ViiV Healthcare/GSK are waived, licensed or otherwise affected.